Ligand Pharmaceuticals Incorporated
LGNDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ligand Pharmaceuticals Incorporated focuses on Biotechnology services and products. Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. The $6.08B market capitalization puts LGND squarely in mid-cap range for its industry. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Market Cap
$6.08B
Beta
0.98
P/E (TTM)
38.75
P/E (Fwd)
26.25
EPS (TTM)
$7.83
EPS (Fwd)
$11.56
ROE
17.1%
ROA
5.2%
Cash
$779.4M
Total Debt
$452.0M
Free CF
$142.1M
52W Change
118.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $779.4M in cash comfortably exceeding the $452.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $142.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 17.1% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $196.2M (2022) to $268.1M (2025), reflecting a 37% increase over the period.
Investors considering Ligand Pharmaceuticals Incorporated should weigh the typical risks associated with LGND's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ligand Pharmaceuticals Incorporated's trajectory.